



Genetic studies of focal segmental glomerulosclerosis: a waste of scientific time?

Alexander J. Howie¹

Received: 24 October 2018 / Revised: 27 November 2018 / Accepted: 28 November 2018
© The Author(s) 2018

Abstract

Many genetic causes of focal segmental glomerulosclerosis (FSGS) have been described. A paradox is that the science in the molecular biology, which generally appears of high quality, is not mirrored by a similarly critical analysis of the renal pathology. FSGS has been applied to such a wide range of conditions that it can reasonably be said to have no useful meaning. Attempts to refine the term have been largely ignored. Study of 252 papers on genetic causes of FSGS found various clinical features. Many papers took the reported diagnosis without question. Few papers reported a pathological review, almost half reported FSGS and up to six other conditions caused by any particular gene, some reported FSGS with recognisable glomerular disorders, over 80% did not apply the Columbia classification, and in nearly all with photomicrographs, the images were not useful for refinement of FSGS. Some workers commented on a lack of genotype-phenotype correlation. One reason is a disregard of the principle that scientific investigation requires an unambiguous definition of the condition studied, to allow others to replicate or refute the findings. Genetic studies of FSGS should use a similarly rigorous approach to renal pathology to that used in molecular biology.

Keywords Focal segmental glomerulosclerosis · Genetics · Renal pathology

Introduction

Many genetic causes of focal segmental glomerulosclerosis (FSGS) have been described. As examples, Gast et al. [1] gave a list of 39 genes associated with FSGS, Preston et al. [2] listed 48, and De Vriese et al. [3] listed 55, separated into renal limited (21) and syndromic (34), although even this last paper did not include some genes mentioned by others, such as Warejko et al. [4]. This means that there are no agreed criteria for identification of genetic causes. Also, sometimes FSGS and steroid-resistant nephrotic syndrome have been regarded as virtually synonymous and not differentiated [5–7]. Other genetic causes of FSGS and/or steroid-resistant nephrotic

syndrome continue to be reported, and any paper attempting to show a definitive list of causative genes is out of date before publication.

The molecular biology in papers on genetic causes is presumably rigorously considered by referees and editors before acceptance by journals. Mutation of a single base pair in an exon of a gene is commonly reported as a significant finding, although other genetic features such as polymorphisms are also said to be associated with FSGS. The mere finding of an alteration in a gene is no longer enough by itself to justify the conclusion that the name of the gene can be added to the list of those in which a mutation can cause FSGS. Various conditions should be satisfied before this can be done, listed and discussed in detail by Lovric et al. [8] and others [4, 6]. For example, detailed experimental functional studies are now often required to support the view that any putative new genetic cause of FSGS is indeed likely to be a cause [e.g. 9, 10].

A scientific paradox considered in this review is the discrepancy between the rigour, precision, close control, reproducibility and generally high quality of the molecular biology and if applicable the experimental work in studies of genetic causes of FSGS and the widespread lack of any of these properties in the selection of cases that are included in reports.

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s00467-018-4161-6>) contains supplementary material, which is available to authorized users.

✉ Alexander J. Howie
a.j.howie@ucl.ac.uk

¹ Department of Pathology, Department of Cellular Pathology, Royal Free Hospital, University College London, London NW3 2QG, UK

Focal segmental glomerulosclerosis

FSGS continues to be used as a diagnosis even though virtually every paper or review accepts that the term has no useful, definable meaning applicable to a single condition [8, 11–13]. This review concentrates on the almost universal neglect of application of the same scientific principles to selection and diagnosis of cases compared with the application of those scientific principles to the molecular biological methods used to study them. The basis of the review is 252 papers published before September 2018, selected by the criterion that at least one mutation or polymorphism in at least one gene was said to be associated with at least one case of so-called FSGS, whether or not there was any further clarification of that term [Supplement]. With such a rapidly developing topic, this selection cannot be comprehensive, but any papers missed will have little effect on the overall conclusions.

FSGS is often defined tautologously as the finding on microscopy of sclerosed areas, meaning areas that appear solid and stain black with periodic acid-methenamine silver, that are segmental, meaning in only part of a glomerular tuft, and focal, meaning not in every glomerulus. There is a view that more detailed pathological study does not contribute to understanding of FSGS. As examples, comments can be found that ‘At a practical therapeutic level all FSGS should be considered equal’ [14] and ‘The etiopathogenesis of FSGS cannot be reliably determined by light microscopy alone’ [3]. Contrary to this view, detailed pathological investigation has shown that cases labelled FSGS can be separated into various types, depending on features such as the position of lesions within glomeruli, the state of the kidney outside glomeruli and other things. For example, when clinical features are also taken into account, such as the clinical presentation and apparent renal mass, the single term FSGS is seen to be completely inadequate and thoroughly misleading for the range of conditions to which it is applied [15–17].

Even the common attempt at refinement by the division into primary and secondary types of FSGS is crude, imprecise and unsatisfactory. What do these terms mean? Is FSGS caused by a genetic disorder primary or secondary or neither? FSGS of presumed genetic cause is often said to be not primary, and so is presumably or explicitly secondary [11, 13, 18], or is explicitly neither primary nor secondary but separate from these [3], or is considered not secondary, and so is presumably or explicitly primary [6, 19, 20]. Bierzynska and Saleem [6] said that patients with non-nephrotic proteinuria and FSGS but without an underlying cause were considered to have primary FSGS, although these do not have recurrence after transplantation, unlike many patients with the nephrotic syndrome and ‘primary’ FSGS. Primary FSGS associated with the nephrotic syndrome is often thought to be caused

by something in the blood, which means that it is secondary to whatever is circulating [6, 12, 20]. This emphasises the inconsistent application of the term primary FSGS. Are not all lesions secondary to some underlying cause? Do primary, ‘secondary’ and genetic forms of FSGS have any connection with each other? If not, what is the use of the term ‘FSGS’?

The Columbia classification of FSGS was an attempt by pathologists to reduce the ambiguity of the term FSGS by the introduction of five types or variants, called cellular, collapsing, hilar, tip and not otherwise specified (NOS) [21]. Even though this classification has flaws, it is better than nothing in its help to nephrologists [17]. For example, the tip variant of FSGS has a better outcome than other variants [20, 22, 23]. Tests of reproducibility have shown that there is agreement between pathologists in application of the Columbia classification [24]. A study of recurrent FSGS in renal allografts showed that four fifths of cases showed the same Columbia variant as the original disease [25].

Selection of cases in genetic causes of focal segmental glomerulosclerosis

There was a range of ways in which people were identified and reported to have a genetic cause of FSGS. Most were found by study of groups with features in common, but some were explicitly reports of a single case or more than one case. The distinction between a case report and a series was not always easy to make, especially in papers about families with an apparently inherited condition. Of the 252 papers, 199 were regarded as series in the broadest sense, including most with familial cases, and 53 as case reports. Familial cases were reported in 71 papers, sporadic cases in 25 and both familial and sporadic cases in 56, while 100 papers did not say whether cases were familial or sporadic. There was a range of ages studied. Only children were included in 119 papers, only adults in 50 and both children and adults in 74, while nine papers did not specify the age of subjects.

Clinical features of cases varied. There were three reasons why there was difficulty in determining precise numbers of subjects with different clinical features. At least 17 papers included patients reported in previous studies, sometimes without identifying which ones were included. Patients with different features were grouped in some papers. Some papers did not even give clinical details. The nephrotic syndrome was a common clinical finding and a common reason for inclusion in series, but sometimes, this was specifically only steroid-resistant nephrotic syndrome, sometimes both steroid-resistant and steroid-sensitive nephrotic syndrome, sometimes unspecified nephrotic syndrome and sometimes not differentiated from non-nephrotic proteinuria. Congenital nephrotic

syndrome was sometimes included with other types of the nephrotic syndrome, sometimes excluded, sometimes the only clinical feature and frequently not mentioned in childhood studies.

For the reasons given, precise numbers of these different features cannot be determined, but at least 145 series appear to have had the nephrotic syndrome as the main or only clinical feature. Other clinical features, if they were mentioned, included such things as non-nephrotic proteinuria, microscopic haematuria, renal failure, hypertension and combinations of features. Some of these were the main reason for inclusion in series.

A diagnosis of FSGS was a reason for selection of cases for study in 70 series, but this was accompanied by a variety of clinical features, and was not necessarily the only reason for selection. Accordingly, there is an overlap between these 70 papers and many with the nephrotic syndrome. Thirteen papers did not specify any clinical features in those with FSGS. Ten papers selected FSGS specifically with the nephrotic syndrome but not all with the same type of nephrotic syndrome, as described above, while 34 papers selected FSGS with the nephrotic syndrome or other clinical features, eight selected either FSGS or the nephrotic syndrome and five selected FSGS with other glomerular disorders, such as IgA nephropathy or thin glomerular basement membrane disease. In some series, particularly on patients with steroid-resistant nephrotic syndrome, some were said to have FSGS even though a renal biopsy was reported to show something else [26], or patients were assumed to have FSGS [27, 28].

In 62 papers, both series and case reports, the reason for inclusion was a variety of syndromes that included renal disease, not necessarily with the nephrotic syndrome. The most numerous syndromes were those with *WT1* mutations, such as Frasier and Denys-Drash syndromes (14 papers), various disorders associated with mitochondrial DNA abnormalities, such as MELAS syndrome and maternally inherited diabetes mellitus and deafness (10), Alport syndrome (6), Charcot-Marie-Tooth syndrome (5), Galloway-Mowat syndrome (3), Pierson syndrome (3) and Schimke immunoosseous dysplasia (3). Among the others were seven with tubular disorders, particularly Dent syndrome (3) and Bartter syndrome (2). Other reasons for inclusion in series were, as examples, that there was a known genetic mutation or polymorphism, or simply that the patients had been referred for genetic testing.

There were various clinical reasons for exclusion of cases from 44 series, particularly causes of secondary FSGS such as reduced renal mass or obesity (28 papers, including 11 with HIV infection) or extrarenal features (8). HIV infection was included in seven other series. The remaining series and case reports either included patients with extrarenal features

(59) or did not mention whether there were any exclusions on clinical grounds (142).

In the 252 papers, 91 excluded an abnormality in at least one relevant gene, such as mutations in *NPHS1* and *NPHS2*, a couple of the earliest genes to be described. In theory, every paper should have searched for all reported genetic causes before an apparently new abnormality was described, which may have been a coincidental and irrelevant finding. Similarly, in theory, whenever any new cause is published, authors of every previous paper should review their cases to see whether that cause was missed, and was a more likely cause or contributor to the condition. Bierzynska and Saleem [6] warned that ‘almost all historical reports of causal variants need to be reassessed against current reference datasets, to filter out those that are no longer deemed causative’.

This overview shows that genetic studies of FSGS had no consistency in the population studied. Although many patients with FSGS had steroid-resistant nephrotic syndrome, some did not. Was the FSGS reported in anyone with steroid-resistant nephrotic syndrome, for example, the same as the FSGS reported in a case of congenital nephrotic syndrome, or an adult with asymptomatic proteinuria, or a child with Alport syndrome or someone with a tubular disorder?

The concept of phenocopies of genetic causes of FSGS or steroid-resistant nephrotic syndrome was introduced by Warejko et al. [4], without an explicit definition. This cannot mean disorders which are genetic but do not affect the same cells as ‘genuine’ genetic causes of FSGS, which often seem to be confined to those purely affecting podocytes [8, 29, 30]. For example, one gene said to cause a phenocopy of genetic causes of FSGS was *GLA*, mutated in Fabry disease, which affects podocytes [31]. The non-phenocopy group of Warejko et al. [4] included genes in the syndromic group of De Vries et al. [3], such as *COQ2*, *INF2*, *LAMB2*, *LMX1B*, *SMARCAL1* and *WT1*, and so genes causing FSGS can affect podocytes and cells outside the kidney. Similarly confusing is the finding that several genetic abnormalities that cause tubular disorders [32] have been reported to cause FSGS, such as *CLCN5*, mutated in Dent disease 1 [33], and *SLC12A1*, mutated in Bartter syndrome type 1 [34], although these are not always included in lists of genetic causes of FSGS. Also overlooked sometimes are mitochondrial DNA mutations reported in cases of FSGS [e.g. 35–39], and glycogen storage diseases said to cause FSGS [40, 41].

The diagnosis of focal segmental glomerulosclerosis in studies

There seemed a readiness of many pathologists to apply the term FSGS and a readiness of those doing the genetic

studies to accept the diagnosis. In only 21 papers (8% of 252) was there a mention that there was a review of light microscopic sections on every renal biopsy or every available biopsy or most biopsies by at least one pathologist. This should in theory give consistency in the cases included and excluded [e.g. 38, 42, 43]. Otherwise, the diagnosis of FSGS in series appeared to have been taken from reports by various pathologists. Why this is important is shown by the finding that in nearly half of the papers, 122 out of 252 (48%), any particular gene was reported to cause not only FSGS, but other glomerular abnormalities. This excludes papers mentioning only global sclerosis of glomeruli as another finding. Commonly reported other diagnoses were minimal change nephropathy, mesangial proliferative glomerulonephritis, IgM nephropathy, membranoproliferative glomerulonephritis, diffuse mesangial sclerosis and congenital nephrotic syndrome of Finnish type, but there were many others. As examples, Chernin et al. [44] reported FSGS and four of these other diagnoses in children with *WT1* mutations, and Sadowski et al. [45] reported FSGS and six other diagnoses, including Alport nephropathy, in children with *NPHS2* mutations. Can genetic abnormalities really cause multiple glomerular disorders, or is a more likely explanation that there was inconsistency between pathologists in these studies?

Sometimes, among conditions as well as FSGS that were reported in particular mutations, unsatisfactory terms appeared, such as ‘minimal unspecific glomerular changes’, ‘unclear (or no) diagnosis’, ‘mild (or minor) glomerular changes’, ‘nonspecific tubulointerstitial nephropathy’, ‘not classifiable’, ‘unclassifiable glomerulopathy’, ‘nonspecific pathology’ and ‘no findings’. This again emphasises how unreliable is mere copying of reports from a variety of pathologists, especially those who are not experts in renal pathology. Also, FSGS was said to occur in glomeruli with diagnoses such as IgA nephropathy [46], diabetic glomerulopathy [47], haemolytic-uraemic syndrome [48], Alport syndrome [49] and thin glomerular basement membranes [50]. Did the patients have two disorders, or were the segmental lesions a complication of the other condition? If they were a complication, would the diagnosis be better as, for example, Alport syndrome with sclerosing glomerular lesions, rather than merely FSGS?

Application of the Columbia classification would be a test of whether a paper attempted to refine the diagnosis of FSGS. Columbia appeared in 2004 [21], although it had been suggested by D’Agati in 2003 [51]. Naturally, only papers published after the classification was published could incorporate it in their findings. The year 2005 was arbitrarily selected as the earliest publication date when Columbia, or various related papers, could be quoted [21,

23, 51–53]. Of 200 papers published in 2005 and afterwards, 140 (70%) did not apply or give a reference to Columbia or relevant papers by D’Agati, and 22 (11%) mentioned Columbia/D’Agati but did not apply the classification. Another 24 papers (12%) did not mention Columbia/D’Agati but included at least one term used in Columbia, almost always just collapsing FSGS, a term which had been introduced earlier [54] and so did not necessarily indicate familiarity with Columbia or application of it. Only 14 (7%) papers both mentioned and applied Columbia. Incidentally, the paper that introduced the term collapsing glomerulopathy said that it was ‘clinically, pathologically, and epidemiologically different from noncollapsing FSGS’ [54], although this distinction has often been ignored [17].

Photomicrographs were common in papers on genetic causes of FSGS, and were included in 86 of 252 papers (34%). A problem is that the figures were almost always just of one glomerulus, and an illustration of one glomerulus in itself generally is of little value. For satisfactory interpretation of a segmental glomerular lesion, the ideal information should be a description of the lesion, its site within the glomerulus, which requires the landmarks of the hilum and tubular origin to be shown, the condition and size of the rest of the glomerulus, the number of glomeruli affected and the condition of the rest of the kidney [17]. Hardly any papers satisfied these requirements. In only 12 papers (14% of 86) could the site of a single type of segmental lesion be identified, and this was at the glomerular hilum in 11 of these. In most papers, 48 of 86 (56%), figures showed segmental lesions that either were at unidentifiable sites in glomeruli or were large or at various sites in glomeruli, meaning that they were late lesions [16]. In 17 papers (20%), there were no segmental lesions, either because the figure was indistinct or definitely had no visible lesion or because an abnormality affected the whole glomerulus, which means it was global rather than segmental, and so could not strictly be called FSGS on any definition. Several of these global lesions were said to show collapsing glomerulopathy, which seems to be conventionally or explicitly included in the term FSGS, even though the changes are distinctive and are generally global, not segmental [17, 54]. In the other nine papers (10%), segmental lesions were seen in association with an identifiable disorder, most commonly IgA nephropathy.

No paper mentioned that the position of segmentally sclerosed glomeruli in the cortex was analysed. Following the work of Rich [55], FSGS is often said to affect glomeruli in the inner/juxtamedullary cortex, although this is probably only true in children [17]. Diffuse mesangial sclerosis appears different because this is reported to be worse in the outer cortex [56], but only one paper appears to have investigated this [57]. In virtually all papers, study not only of

glomeruli but of the whole kidney tissue in a biopsy sample was unsatisfactory [17].

Why this is important

These findings on the selection, diagnosis, description and illustration of cases show that the literature on genetic causes of FSGS is in confusion. One reason why this is important is because the first requirement for study of any condition is to have a precise definition of that condition so that as in any scientific study, other workers can investigate and replicate or refute the original findings. At the moment, there can be little certainty that any paper on FSGS is studying the same condition as any other paper. The confused state of genetics of FSGS contrasts sharply with the relatively much more straightforward genetics of membranous nephropathy, a diagnosis that is uncontroversial compared with FSGS [58]. The critical scientific principles applied to the molecular biology do not appear to have been applied to interpretation of the pathological findings of changes called FSGS. A suggested solution for any proposed study is that those working on the genetics do not take a diagnosis of FSGS at face value unless there has been a thorough review of renal biopsy specimens by a pathologist familiar with the latest ideas on segmental sclerosing disorders, and there is an attempt to classify the segmental lesions. Barisoni and others investigated concordance between pathologists in identification of various features in renal biopsy specimens [59]. They suggested that rather than concentration on single features of segmental glomerular sclerosis, which gave inconsistent concordance, better concordance would be produced by use by pathologists of ‘the totality of the histopathology to arrive at a diagnosis’. This has been suggested previously [15–17].

Another reason why this is important is related to understanding of the pathogenesis of segmental lesions. A few papers reporting mitochondrial DNA mutations have shown that the lesions in affected glomeruli are at the vascular pole or hilum and are associated with abnormalities of arterioles [35–37, 39]. Although this does not explain how the lesions develop, it suggests where research could concentrate to find out the pathogenesis. Similarly, a few papers reporting segmental lesions in kidneys with genetic tubular disorders and glycogen storage disorders have indicated that these lesions may be consequences of glomerular functional overload following a reduction in nephron numbers [34, 40, 41].

Hardly any other papers suggested a mechanism of development of segmental sclerosing lesions, other than vague ideas that the lesions were due to podocyte disorders, which would be expected to produce lesions randomly distributed

in glomeruli [17]. One paper, not included in the series of 252 papers because it avoided use of the term FSGS as a diagnosis, was Ozaltin et al. [60] on *DGKE* variants causing a glomerular microangiopathy: ‘There were also secondary focal and segmental sclerotic glomeruli, which could be seen in the advanced stage of any glomerulopathy’. Although most genes said to cause FSGS are expressed in podocytes [8, 29, 30], few have suggested how genetic abnormalities could cause segmental sclerosing lesions. A rare example is Henderson et al. [61], who found that perihilar segmental lesions, typical of glomerular overload or hyperperfusion or hyperfiltration or post adaptive changes [17], were common in kidneys with *ACTN4* mutations, even though some biopsies did not seem to show significant loss of renal mass, nor glomerular enlargement. They speculated that podocytes with *ACTN4* mutations were less mechanically robust than normal podocytes, and more sensitive to damage by normal glomerular capillary pressures. No papers analysed the distribution of segmentally sclerosed glomeruli in the cortex to see if genetic disorders showed the typical childhood pattern, with juxtamedullary glomeruli affected first [17, 55].

A more scientific approach to all cases of FSGS may reveal more precise genotype-phenotype correlations than are currently known. Until this is done, the study of genetic causes of FSGS will remain unsatisfactory. Some workers have expressed disillusionment with reported renal biopsy findings. These include Bierzynska et al. [62], who wrote, ‘Biopsy reports did not correlate in any systematic way with genetic results identified’, and Schultheiss et al. [63], whose paper was entitled ‘No evidence for genotype/phenotype correlation in *NPHS1* and *NPHS2* mutations’. The importance of phenotyping in genetic studies, including the renal biopsy diagnosis, has been stressed by others [45, 64]. There is the possibility that there is no correlation between any particular genetic abnormality and the glomerular changes it produces, but until there is a rigorous test of this, no one will know. A more critical approach to FSGS is necessary to reduce the confusion about this ‘overused and misunderstood descriptive phrase’ [65].

Acknowledgements I am grateful to Professor Detlef Bockenhauer for discussions about this topic and for his encouragement.

Compliance with ethical standards

Not relevant.

Conflict of interest The author declares that he has no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

- Gast C, Pengelly RJ, Lyon M, Bunyan DJ, Seaby EG, Graham N, Venkat-Raman G, Ennis S (2016) Collagen (*COL4A*) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis. *Nephrol Dial Transplant* 31:961–970
- Preston R, Stuart HM, Lennon R (2018) Genetic testing in steroid-resistant nephrotic syndrome: why, who, when and how? *Pediatr Nephrol*. <https://doi.org/10.1007/s00467-017-3838-6>
- De Vriese AS, Sethi S, Nath KA, Glasscock RJ, Fervenza FC (2018) Differentiating primary, genetic, and secondary FSGS in adults: a clinicopathologic approach. *J Am Soc Nephrol* 29:759–774
- Warejko JK, Tan W, Daga A, Schapiro D, Lawson JA, Shril S, Lovric S, Ashraf S, Rao J, Hermle T, Schwan TJ, Widmeier E, Majmundar AJ, Schneider R, Gee HY, Schmidt JM, Vivante A, van der Ven AT, Ityel H, Chen J, Sadowski CE, Kohl S, Pabst WL, Nakayama M, Somers MJG, Rodig NM, Daouk G, Baum M, Stein DR, Ferguson MA, Traum AZ, Soliman NA, Kari JA, El Desoky S, Fathy H, Zenker M, Bakkaloglu SA, Muller D, Noyan A, Ozaltin F, Cadnapaphornchai MA, Hashmi S, Hopcian J, Kopp JB, Benador N, Bockenbauer D, Bogdanovic R, Stajic N, Chernin G, Ettenger R, Fehrenbach H, Kemper M, Munarriz RL, Podracka L, Buscher R, Serdaroglu E, Tasic V, Mane S, Lifton RP, Braun DA, Hildebrandt F (2018) Whole exome sequencing of patients with steroid-resistant nephrotic syndrome. *Clin J Am Soc Nephrol* 13:53–62
- Benoit G, Machuca E, Heidet L, Antignac C (2010) Hereditary kidney diseases: highlighting the importance of classical Mendelian phenotypes. *Ann N Y Acad Sci* 1214:83–98
- Bierzynska A, Saleem MA (2017) Deriving and understanding the risk of post-transplant recurrence of nephrotic syndrome in the light of current molecular and genetic advances. *Pediatr Nephrol*. <https://doi.org/10.1007/s00467-017-3793-2>
- Bierzynska A, Soderquest K, Dean P, Colby E, Rollason R, Jones C, Inward CD, McCarthy HJ, Simpson MA, Lord GM, Williams M, Welsh GI, Koziell AB, Saleem MA (2017) *MAGI2* mutations cause congenital nephrotic syndrome. *J Am Soc Nephrol* 28:1614–1621
- Lovric S, Ashraf S, Tan W, Hildebrandt F (2016) Genetic testing in steroid-resistant nephrotic syndrome: when and how? *Nephrol Dial Transplant* 31:1802–1813
- Hermle T, Schneider R, Schapiro D, Braun DA, van der Ven AT, Warejko JK, Daga A, Widmeier E, Nakayama M, Jobst-Schwan T, Majmundar AJ, Ashraf S, Rao J, Finn LS, Tasic V, Hernandez JD, Bagga A, Jalalah SM, El Desoky S, Kari JA, Laricchia KM, Lek M, Rehm HL, MacArthur DG, Mane S, Lifton RP, Shril S, Hildebrandt F (2018) *GAPVD1* and *ANKFY1* mutations implicate RAB5 regulation in nephrotic syndrome. *J Am Soc Nephrol* 29:2123–2138
- Sato Y, Tsukaguchi H, Morita H, Higasa K, Tran MTN, Hamada M, Usui T, Morito N, Horita S, Hayashi T, Takagi J, Yamaguchi I, Nguyen HT, Harada M, Inui K, Maruta Y, Inoue Y, Koiwa F, Sato H, Matsuda F, Ayabe S, Mizuno S, Sugiyama F, Takahashi S, Yoshimura A (2018) A mutation in transcription factor MAFB causes focal segmental glomerulosclerosis with Duane retraction syndrome. *Kidney Int* 94:396–407
- Bose B, Cattran D (2014) Glomerular diseases: FSGS. *Clin J Am Soc Nephrol* 9:626–632
- D'Agati VD (2012) Pathobiology of focal segmental glomerulosclerosis: new developments. *Curr Op Neph Hypertens* 21:243–250
- Sethi S, Glasscock RJ, Fervenza FC (2015) Focal segmental glomerulosclerosis: towards a better understanding for the practicing nephrologist. *Nephrol Dial Transplant* 30:375–384
- Cattran DC (1998) Are all patients with idiopathic focal segmental glomerulosclerosis (FSGS) created equal? *Nephrol Dial Transplant* 13:1107–1109
- Howie AJ, Lee SJ, Green NJ, Newbold KM, Kizaki T, Koram A, Richards NT, Michael J, Adu D (1993) Different clinicopathological types of segmental sclerosing glomerular lesions in adults. *Nephrol Dial Transplant* 8:590–599
- Howie AJ, Pankhurst T, Sarioglu S, Turhan N, Adu D (2005) Evolution of nephrotic-associated focal segmental glomerulosclerosis and relation to the glomerular tip lesion. *Kidney Int* 67:987–1001
- Howie AJ (2011) Problems with 'focal segmental glomerulosclerosis. *Pediatr Nephrol* 26:1197–1205
- Chen YM, Liapis H (2015) Focal segmental glomerulosclerosis: molecular genetics and targeted therapies. *BMC Nephrol* 16:101
- Nguyen TG, Goldschmeding R, van den Heuvel LP (2014) Genetic testing for podocyte genes in sporadic focal segmental glomerulosclerosis. *Nephrol Dial Transplant* 29:1985–1986
- Fogo AB (2015) Causes and pathogenesis of focal segmental glomerulosclerosis. *Nat Rev Nephrol* 11:76–87
- D'Agati VD, Fogo AB, Bruijn JA, Jennette JC (2004) Pathologic classification of focal segmental glomerulosclerosis: a working proposal. *Am J Kidney Dis* 43:368–382
- Stokes MB, Valeri AM, Markowitz GS, D'Agati VD (2006) Cellular focal segmental glomerulosclerosis: clinical and pathologic features. *Kidney Int* 70:1783–1792
- D'Agati VD, Alster JM, Jennette JC, Thomas DB, Pullman J, Savino DA, Cohen AH, Gipson DS, Gassman JJ, Radeva MK, Moxey-Mims MM, Friedman AL, Kaskel FJ, Trachtman H, Alpers CE, Fogo AB, Greene TH, Nast CC (2013) Association of histologic variants in FSGS clinical trial with presenting features and outcomes. *Clin J Am Soc Nephrol* 8:399–406
- Meehan SM, Chang A, Gibson IW, Kim L, Kambham N, Laszik Z (2013) A study of interobserver reproducibility of morphologic lesions of focal segmental glomerulosclerosis. *Virchows Arch* 462:229–237
- Ijpelaar DHT, Farris AB, Goemaere N, Amann K, Goldschmeding R, Nguyen TQ, Farkash E, van den Heuvel MC, de Heer E, Bruijn JA, Colvin RB, Bajema IM (2008) Fidelity and evolution of recurrent FSGS in renal allografts. *J Am Soc Nephrol* 19:2219–2224
- Bertelli R, Ginevri F, Caridi G, Dagnino M, Sandrini S, Di Duca M, Emma F, Sanna-Cherchi S, Scolari F, Neri TM, Murer L, Massella L, Basile G, Rizzoni G, Perfumo F, Ghiggeri GM (2003) Recurrence of focal segmental glomerulosclerosis after renal transplantation in patients with mutations of podocin. *Am J Kidney Dis* 41:1314–1321
- McKenzie LM, Hendrickson SL, Briggs WA, Dart RA, Korbet SM, Mokrzycki MH, Kimmel PL, Ahuja TS, Berns JS, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Cho M, Zhou YC, Binns-Roemer E, Kirk GD, Kopp JB, Winkler CA

- (2007) *NPHS2* variation in sporadic focal segmental glomerulosclerosis. *J Am Soc Nephrol* 18:2987–2995
28. Gasser DL, Winkler CA, Peng M, An P, McKenzie LM, Kirk GD, Shi Y, Xie LX, Marbois BN, Clarke CF, Kopp JB (2013) Focal segmental glomerulosclerosis is associated with a *PDSS2* haplotype and, independently, with a decreased content of coenzyme Q10. *Am J Physiol Renal Physiol* 305:F1228–F1238
 29. Zenker M, Machuca E, Antignac C (2009) Genetics of nephrotic syndrome: new insights into molecules acting at the glomerular filtration barrier. *J Mol Med* 87:849–857
 30. Akchurin O, Reidy KJ (2015) Genetic causes of proteinuria and nephrotic syndrome: impact on podocyte pathobiology. *Pediatr Nephrol* 30(2):21–233
 31. Zarate YA, Hopkin RJ (2008) Fabry's disease. *Lancet* 372:1427–1435
 32. Ashton EJ, Legrand A, Benoit V, Roncelin I, Venisse A, Zennaro MC, Jeunemaitre X, Iancu D, van't Hoff WG, Walsh SB, Godefroid N, Rottthier A, Del Favero J, Devuyt O, Schaefer F, Jenkins LA, Kleta R, Dahan K, Vargas-Poussou R, Bockenhauer D (2018) Simultaneous sequencing of 37 genes identified causative mutations in the majority of children with renal tubulopathies. *Kidney Int* 93:961–967
 33. Frishberg Y, Dinour D, Belostotsky R, Becker-Cohen R, Rinat C, Feinstein S, Navon-Elkan P, Ben-Shalom E (2009) Dent's disease manifesting as focal glomerulosclerosis: is it the tip of the iceberg? *Pediatr Nephrol* 24:2369–2373
 34. Yamazaki H, Nozu K, Narita I, Nagata M, Nozu Y, Fu XJ, Matsuo M, Iijima K, Gejyo F (2009) Atypical phenotype of type I Bartter syndrome accompanied by focal segmental glomerulosclerosis. *Pediatr Nephrol* 24:415–418
 35. Moulouguet Doleris L, Hill GS, Chedin P, Nochy D, Bellanne-Chantelot C, Hanslik T, Bedrossian J, Caillat-Zucman S, Cahen-Varsaux J, Bariety J (2000) Focal segmental glomerulosclerosis associated with mitochondrial cytopathy. *Kidney Int* 58:1851–1858
 36. Guillausseau PJ, Massin P, Dubois-LaForgue D, Timsit J, Virally M, Gin H, Bertin E, Blicke JF, Bouhanick B, Cahen J, Caillat-Zucman S, Charpentier G, Chedin P, Derrien C, Ducluzeau PH, Grimaldi A, Guerci B, Kaloustian E, Murat A, Olivier F, Paques M, Paquis-Flucklinger V, Porokhov B, Samuel-Lajeunesse J, Vialettes B (2001) Maternally inherited diabetes and deafness: a multicenter study. *Ann Intern Med* 134:721–728
 37. Segawa-Takaeda C, Takeda S, Ieki Y, Takazakura E, Haratake J, Wada T, Yokoyama H (2002) Focal glomerulosclerosis expanding from the glomerular vascular pole in a Japanese male with mitochondrial-DNA mutation. *Nephrol Dial Transplant* 17:172–174
 38. Guery B, Choukroun G, Noel LH, Clavel P, Rotig A, Lebon S, Rustin P, Bellane-Chantelot C, Mougnot B, Grunfeld JP, Chauveau D (2003) The spectrum of systemic involvement in adults presenting with renal lesion and mitochondrial tRNA(Leu) gene mutation. *J Am Soc Nephrol* 14:2099–2108
 39. Piccoli GB, Bonino LD, Campisi P, Vigotti FN, Ferraresi M, Fassio F, Brocheriou I, Porpiglia F, Restagno G (2012) Chronic kidney disease, severe arterial and arteriolar sclerosis and kidney neoplasia: on the spectrum of kidney involvement in MELAS syndrome. *BMC Nephrol* 13:9
 40. Chen YT, Coleman RA, Scheinman JI, Kolbeck PC, Sidbury JB (1988) Renal disease in type I glycogen storage disease. *New Engl J Med* 318:7–11
 41. Baker L, Dahlem S, Goldfarb S, Kern EFO, Stanley CA, Egler J, Olshan JS, Heyman S (1989) Hyperfiltration and renal disease in glycogen storage disease, type I. *Kidney Int* 35:1345–1350
 42. Bantis C, Heering PJ, Stangou M, Kouri NM, Schwandt C, Memmos D, Rump LC, Ivens K (2011) Influence of aldosterone synthase gene C-344T polymorphism on focal segmental glomerulosclerosis. *Nephrology* 16:730–735
 43. Jinks RN, Puffenberger EG, Baple E, Harding B, Crino P, Fogo AB, Wenger O, Xin B, Koehler AE, McGlincy MH, Provencher MM, Smith JD, Tran L, Al Turki S, Chioza BA, Cross H, Harlalka GV, Hurles ME, Maroofian R, Heaps AD, Morton MC, Stempak L, Hildebrandt F, Sadowski CE, Zaritsky J, Campellone K, Morton DH, Wang H, Crosby A, Strauss KA (2015) Recessive nephrocerebellar syndrome on the Galloway-Mowat syndrome spectrum is caused by homozygous protein-truncating mutations of *WDR73*. *Brain* 138:2173–2190
 44. Chemin G, Vega-Warner V, Schoeb DS, Heeringa SF, Ovunc B, Saisawat P, Cleper R, Ozaltin F, Hildebrandt F (2010) Genotype/phenotype correlation in nephrotic syndrome caused by *WT1* mutations. *Clin J Am Soc Nephrol* 5:1655–1662
 45. Sadowski CE, Lovric S, Ashraf S, Pabst WL, Gee HY, Kohl S, Engelmann S, Vega-Warner FH, Halbritter J, Somers MJ, Tan W, Shril S, Fessi I, Lifton RP, Bockenhauer D, El-Desoky S, Kari JA, Zenker M, Kemper MJ, Mueller D, Fathy HM, Soliman NA, Hildebrandt F (2015) A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. *J Am Soc Nephrol* 26:1279–1289
 46. Lowik MM, Hol FA, Steenbergen EJ, Wetzels JFM, van den Heuvel LPWJ (2005) Mitochondrial tRNA^{Leu(UUR)} mutation in a patient with steroid-resistant nephrotic syndrome and focal segmental glomerulosclerosis. *Nephrol Dial Transplant* 20:336–341
 47. Nakamura S, Yoshinari M, Doi Y, Yoshizumi H, Katafuchi R, Yokomizo Y, Nishiyama K, Wakisaka M, Fujishima M (1999) Renal complications in patients with diabetes mellitus associated with an a to G mutation of mitochondrial DNA at the 3243 position of leucine tRNA. *Diabetes Res Clin Pract* 44:183–189
 48. Sethi S, Fervenza FC, Zhang Y, Smith RJH (2012) Secondary focal and segmental glomerulosclerosis associated with single-nucleotide polymorphisms in the genes encoding complement factor H and C3. *Am J Kidney Dis* 60:316–321
 49. Ma J, Pan X, Wang Z, Wang Y, Feng X, Ren H, Zhang W, Chen X, Wang W, Chen N (2011) Twenty-one novel mutations identified in the *COL4A5* gene in Chinese patients with X-linked Alport's syndrome confirmed by skin biopsy. *Nephrol Dial Transplant* 26:4003–4010
 50. Papazachariou L, Demosthenous P, Pieri M, Papagregoriou G, Savva I, Stavrou C, Zavros M, Athanasiou Y, Ioannou K, Patsias C, Panagides A, Potamitis C, Demetriou K, Prikis M, Hadjigavriel M, Kkolou M, Loukaidou P, Pastelli A, Michael A, Lazarou A, Arsalis M, Damianou L, Goutziamani I, Soloukides A, Yioukas L, Elia A, Zouvani I, Polycarpou P, Pierides A, Voskarides K, Deltas C (2014) Frequency of *COL4A3/COL4A4* mutations amongst families segregating glomerular microscopic hematuria and evidence for activation of the unfolded protein response. Focal and segmental glomerulosclerosis is a frequent development during ageing. *PLoS One* 9:e115015
 51. D'Agati VD (2003) Pathologic classification of focal segmental glomerulosclerosis. *Sem Nephrol* 23:117–134
 52. D'Agati VD (2008) The spectrum of focal segmental glomerulosclerosis: new insights. *Curr Op Neph Hypertens* 17:271–281
 53. D'Agati VD, Kaskel FJ, Falk RJ (2011) Focal segmental glomerulosclerosis. *N Engl J Med* 365:2398–2411
 54. Detwiler RK, Falk RJ, Hogan SL, Jennette JC (1994) Collapsing glomerulopathy: a clinically and pathologically distinct variant of focal segmental glomerulosclerosis. *Kidney Int* 45:1416–1424

55. Rich AR (1957) A hitherto undescribed vulnerability of the juxtamedullary glomeruli in lipid nephrosis. *Bull Johns Hopkins Hosp* 100:173–186
56. Habib R (1993) Nephrotic syndrome in the first year of life. *Pediatr Nephrol* 7:347–353
57. Hinkes B, Wiggins RC, Gbadegesin R, Vlangos CN, Seelow D, Nurnberg G, Garg P, Verma R, Chaib H, Hoskins BE, Ashraf S, Becker C, Hennies HC, Goyal M, Wharram BL, Schachter AD, Mudumana S, Drummond I, Kerjaschki D, Waldherr R, Dietrich A, Ozaltin F, Bakkaloglu A, Cleper R, Basel-Vanagaite L, Pohl M, Griebel M, Tsygin AN, Soylu A, Muller D, Sorli CS, Bunney TD, Katan M, Liu J, Attanasio M, O'Toole JF, Hasselbacher K, Mucha B, Otto EA, Airik R, Kispert A, Kelley GG, Smrcka AV, Gudermann T, Holzman LB, Nurnberg P, Hildebrandt F (2006) Positional cloning uncovers mutations in *PLCE1* responsible for a nephrotic syndrome variant that may be reversible. *Nature Genet* 38:1397–1405
58. Gupta S, Kottgen A, Hoxha E, Brenchley P, Bockenhauer D, Stanescu HC, Kleta R (2018) Genetics of membranous nephropathy. *Nephrol Dial Transplant* 33:1493–1502
59. Barisoni L, Troost JP, Nast C, Bagnasco S, Avila-Casado C, Hodgins J, Palmer M, Rosenberg A, Gasim A, Liensziewski C, Merlino L, Chien HP, Chang A, Meehan SM, Gaut J, Song P, Holzman L, Gibson D, Kretzler M, Gillespie BW, Hewitt SM (2016) Reproducibility of the NEPTUNE descriptor-based scoring system on whole-slide images and histologic and ultrastructural digital images. *Mod Pathol* 29:671–684
60. Ozaltin F, Li B, Rauhauser A, An SW, Soylemezoglu O, Gonul II, Taskiran EZ, Ibsirlioglu T, Korkmaz E, Bilginer Y, Duzova A, Ozen S, Topaloglu R, Besbas N, Ashraf S, Yong Du Y, Liang C, Chen P, Lu D, Vадnagara K, Arbuckle S, Lewis D, Wakeland B, Quigg RJ, Ransom RF, Wakeland EK, Topham MK, Bazan NG, Mohan C, Hildebrandt F, Bakkaloglu A, Huang CL, Attanasio M (2013) *DGKE* variants cause a glomerular microangiopathy that mimics membranoproliferative GN. *J Am Soc Nephrol* 24:377–384
61. Henderson JM, Alexander MP, Pollak MR (2009) Patients with *ACTN4* mutations demonstrate distinctive features of glomerular injury. *J Am Soc Nephrol* 20:961–968
62. Bierzynska A, McCarthy HJ, Soderquest K, Sen ES, Colby E, Ding WY, Nabhan MM, Kerecuk L, Hegde S, Hughes D, Marks S, Feather S, Jones C, Webb NJA, Ognjanovic M, Christian M, Gilbert RD, Sinha MD, Lord GM, Simpson M, Koziell AB, Welsh GI, Saleem MA (2017) Genomic and clinical profiling of a national nephrotic syndrome cohort advocates a precision medicine approach to disease management. *Kidney Int* 91:937–947
63. Schultheiss M, Ruf RG, Mucha BE, Wiggins R, Fuchshuber A, Lichtenberger A, Hildebrandt F (2004) No evidence for genotype/phenotype correlation in *NPHS1* and *NPHS2* mutations. *Pediatr Nephrol* 19:1340–1348
64. Snoek R, van Eerde AM, Knoers NVAM (2017) Importance of reliable variant calling and clear phenotyping when reporting on gene panel testing in renal disease. *Kidney Int* 92:1325–1327
65. Pollak MR, Alexander MP, Henderson JM (2007) A case of familial kidney disease. *Clin J Am Soc Nephrol* 2:1367–1374